MarketCapExport financials
iRhythm Technologies (IRTC)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
iRhythm Technologies Balance Sheet 2025-2011 | IRTC
Brief balance sheet overview of iRhythm Technologies
Balance sheet changes are traced across five available annual reports between 2021 and 2025.
Assets reached $1 billion, compared with $463 million at the beginning. Growth of +120.3% and CAGR near 21.8% show active expansion.
Liability growth of +372.8% exceeded asset growth of +120.3%, increasing reliance on outside funding.
Internal capital represents 15% of the balance sheet versus 60.4% five periods ago. The cushion is thin.
Net debt moved below zero to -$154.3 million, reflecting surplus cash over debt.
Cash equals 23.1% of the balance sheet, compared with 27.6% five periods ago. This is the readily available cushion.
Retained earnings are negative at -$803.4 million. This reduces the formal capital cushion, although large shareholder returns may have contributed.
What the balance sheet shows
iRhythm Technologies's balance sheet profile is moderate. It should be considered alongside profitability, cash flow and liability maturities.
Annual Balance Sheet iRhythm Technologies
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-154 M | -329 M | 13.9 M | -30.9 M | -107 M | -67.3 M | 14.5 M | 73.2 M | 25.3 M | 35 M | 5.34 M | -2.36 M | - | - | - |
Long Term Debt |
65 M | 74.6 M | 35 M | 34.9 M | 9.69 M | 21.3 M | 33 M | 34.9 M | 32.5 M | 32.2 M | 30.6 M | 6.26 M | - | - | - |
Long Term Debt Current |
16.7 M | 15.9 M | 15.2 M | 13 M | 11.1 M | - | - | - | 1.49 M | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 119 M | 35.1 M | 32.7 M | 32.4 M | 131 M | 94.2 M | - | - | - |
Total Current Liabilities |
152 M | 111 M | 107 M | 89.1 M | 87.9 M | 65.7 M | 52.1 M | 30.3 M | 20.9 M | 13.2 M | - | - | - | - | - |
Total Liabilities |
867 M | 841 M | 223 M | 208 M | 183 M | 170 M | 171 M | 65.3 M | 53.6 M | 45.6 M | 139 M | 99.1 M | - | - | - |
Deferred Revenue |
4.2 M | 2.93 M | 3.31 M | 3.05 M | 3.05 M | 930 K | 1.25 M | 1.24 M | 1.24 M | 947 K | 506 K | 421 K | - | - | - |
Retained Earnings |
-803 M | -759 M | -646 M | -522 M | -406 M | -305 M | -260 M | -204 M | -157 M | -127 M | -106 M | -83.5 M | - | - | - |
Total Assets |
1.02 B | 931 M | 433 M | 448 M | 463 M | 512 M | 306 M | 120 M | 133 M | 138 M | 37.9 M | 18.5 M | - | - | - |
Cash and Cash Equivalents |
236 M | 420 M | 36.2 M | 78.8 M | 128 M | 88.6 M | 20.5 M | 20 M | 8.67 M | 51.6 M | 25.2 M | 8.62 M | - | - | - |
Book Value |
153 M | 90.9 M | 210 M | 240 M | 280 M | 342 M | 135 M | 54.4 M | 79.6 M | 92.6 M | -102 M | -80.5 M | - | - | - |
Total Shareholders Equity |
153 M | 90.9 M | 210 M | 240 M | 280 M | 342 M | 135 M | 52.1 M | 79.3 M | 92.6 M | -102 M | -80.5 M | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet iRhythm Technologies
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
59.3 M | 62.2 M | 65 M | 67.7 M | 70.4 M | 72.1 M | 74.6 M | 74 M | 76.2 M | 77.6 M | 79.7 M | 34.9 M | 34.9 M | 34.9 M | 34.9 M | 34.9 M | - | 34.9 M | 9.69 M | 12.6 M | 15.5 M | 18.4 M | 21.3 M | 24.3 M | 21.3 M | 21.3 M | 33 M | 34.9 M | 33 M | 33 M | 34.9 M | 32.6 M | 34.9 M | 34.9 M | 32.5 M | 32.5 M | 32.5 M | 32.5 M | 32.2 M | 32.2 M | 32.2 M | 32.2 M | 30.6 M | 30.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
907 M | 845 M | 867 M | 873 M | 860 M | 839 M | 841 M | 838 M | 820 M | 819 M | 223 M | 220 M | 206 M | 200 M | 208 M | 201 M | - | 184 M | 183 M | 184 M | 179 M | 169 M | 170 M | 170 M | 170 M | 170 M | 171 M | 171 M | 171 M | 171 M | 65.4 M | 65.4 M | 65.3 M | 65.3 M | 54 M | 53.6 M | 53.6 M | 53.6 M | 45.6 M | 45.6 M | 45.6 M | 45.6 M | 42.4 M | 42.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
4.2 M | 4.06 M | 4.2 M | 4.22 M | 3.5 M | 3.28 M | 2.93 M | 3.03 M | 3.15 M | 3.07 M | 3.31 M | 3.38 M | 3.7 M | 3.49 M | 3.05 M | 3 M | - | 2.93 M | 3.05 M | 2.37 M | 2.51 M | 1.42 M | 930 K | 930 K | 930 K | 930 K | 1.25 M | 1.25 M | 1.25 M | 1.25 M | 1.22 M | 1.22 M | 1.24 M | 1.1 M | 1.24 M | 904 K | 557 K | 980 K | 947 K | 947 K | 947 K | 947 K | 506 K | 506 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-818 M | -817 M | -803 M | -809 M | -804 M | -790 M | -759 M | -758 M | -711 M | -691 M | -646 M | -607 M | -580 M | -561 M | -522 M | -502 M | - | -457 M | -406 M | -374 M | -350 M | -332 M | -305 M | -305 M | -305 M | -305 M | -260 M | -260 M | -260 M | -260 M | -206 M | -206 M | -204 M | -204 M | -157 M | -157 M | -157 M | -157 M | -127 M | -127 M | -127 M | -127 M | -106 M | -106 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
1.09 B | 1.01 B | 1.02 B | 995 M | 964 M | 926 M | 931 M | 910 M | 919 M | 910 M | 433 M | 440 M | 429 M | 422 M | 448 M | 440 M | - | 429 M | 463 M | 480 M | 485 M | 478 M | 512 M | 512 M | 512 M | 512 M | 306 M | 306 M | 306 M | 306 M | 118 M | 118 M | 120 M | 120 M | 133 M | 133 M | 133 M | 133 M | 138 M | 138 M | 138 M | 138 M | 37.9 M | 37.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
247 M | 240 M | 236 M | 256 M | 309 M | 375 M | 420 M | 520 M | 551 M | 520 M | 36.2 M | 47.5 M | 61.6 M | 52.8 M | 78.8 M | 71.2 M | 101 M | 94.8 M | 128 M | 167 M | 139 M | 137 M | 88.6 M | 88.6 M | 88.6 M | 88.6 M | 20.5 M | 20.5 M | 20.5 M | 20.5 M | 20 M | 20 M | 20 M | 20 M | 8.67 M | 8.67 M | 8.67 M | 8.67 M | 51.6 M | 51.6 M | 51.6 M | 51.6 M | 25.2 M | 25.2 M | - | - | 8.62 M | - | - | - | 7.1 M | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
186 M | 161 M | 153 M | 122 M | 104 M | 86.7 M | 90.9 M | 71.8 M | 99.2 M | 90.3 M | 210 M | 220 M | 224 M | 222 M | 240 M | 239 M | - | 245 M | 280 M | 296 M | 306 M | 310 M | 342 M | 342 M | 342 M | 342 M | 135 M | 135 M | 135 M | 135 M | 52.1 M | 52.1 M | 54.4 M | 54.4 M | 79.3 M | 79.6 M | 79.6 M | 79.6 M | 92.6 M | 92.6 M | 92.6 M | 92.6 M | -4.53 M | -4.53 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
186 M | 161 M | 153 M | 122 M | 104 M | 86.7 M | 90.9 M | 71.8 M | 99.2 M | 90.3 M | 210 M | 220 M | 224 M | 222 M | 240 M | 239 M | 245 M | 245 M | 280 M | 296 M | 306 M | 310 M | 342 M | 342 M | 342 M | 342 M | 135 M | 135 M | 135 M | 135 M | 52.1 M | 52.1 M | 54.4 M | 54.4 M | 79.3 M | 79.6 M | 79.6 M | 79.6 M | 93 M | 92.6 M | 92.6 M | 92.6 M | -102 M | -102 M | - | - | -80.5 M | - | - | - | -65.6 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of iRhythm Technologies, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Medical instruments
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M |  USA |
 |
electroCore
ECOR
|
$ 11.42 | 2.46 % | $ 96.9 K | USA |
 |
Alcon
ALC
|
$ 65.39 | 0.02 % | $ 32.3 B |  Schweiz |
 |
Glaukos Corporation
GKOS
|
$ 153.49 | 0.19 % | $ 8.78 B | USA |
 |
Haemonetics Corporation
HAE
|
$ 106.82 | 0.01 % | $ 5.04 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 8.05 | 1.64 % | $ 357 M | USA |
 |
InfuSystem Holdings
INFU
|
$ 12.7 | 2.26 % | $ 262 M | USA |
 |
Intuitive Surgical
ISRG
|
$ 398.3 | 0.06 % | $ 142 B | USA |
 |
AngioDynamics
ANGO
|
$ 15.51 | 0.26 % | $ 644 M | USA |
 |
Repro Med Systems
KRMD
|
$ 3.27 | 2.42 % | $ 151 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 80.58 | 0.12 % | $ 1.82 B | USA |
 |
Microbot Medical
MBOT
|
$ 1.31 | 0.36 % | $ 60 M |  Israel |
 |
Merit Medical Systems
MMSI
|
$ 87.07 | 0.1 % | $ 5.15 B | USA |
 |
Nephros
NEPH
|
$ 4.29 | 2.88 % | $ 45.5 M | USA |
 |
Envista Holdings Corporation
NVST
|
$ 23.82 | 0.41 % | $ 4 B | USA |
 |
OraSure Technologies
OSUR
|
$ 3.99 | 8.13 % | $ 293 M | USA |
 |
Pro-Dex
PDEX
|
$ 71.94 | 0.12 % | $ 232 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 51.98 | 0.25 % | $ 3.5 B | USA |
 |
Repligen Corporation
RGEN
|
$ 184.53 | 0.81 % | $ 10.4 M | USA |
 |
Retractable Technologies
RVP
|
$ 0.7 | 0.36 % | $ 21 M | USA |
 |
AtriCure
ATRC
|
$ 59.96 | 1.91 % | $ 2.86 B | USA |
 |
STAAR Surgical Company
STAA
|
$ 19.8 | 1.62 % | $ 981 M | USA |
 |
STERIS plc
STE
|
$ 209.98 | 0.61 % | $ 20.6 B | USA |
 |
Stereotaxis
STXS
|
$ 1.32 | 2.94 % | $ 120 M | USA |
 |
BioLife Solutions
BLFS
|
$ 37.74 | 0.37 % | $ 1.8 B | USA |
 |
Baxter International
BAX
|
$ 23.49 | 0.17 % | $ 12.1 B | USA |
 |
Utah Medical Products
UTMD
|
$ 75.01 | 2.93 % | $ 243 M | USA |
 |
West Pharmaceutical Services
WST
|
$ 375.87 | 1.29 % | $ 27.2 B | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 182.52 | 0.01 % | $ 52.5 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 9.78 | 0.05 % | $ 1.95 B | USA |
 |
The Cooper Companies
COO
|
$ 56.07 | 1.41 % | $ 11.2 B | USA |
 |
ICU Medical
ICUI
|
$ 163.32 | 1.45 % | $ 4.02 B | USA |
 |
Milestone Scientific
MLSS
|
$ 0.42 | 4.73 % | $ 34.5 M | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 121.75 | 0.08 % | $ 5.43 B | USA |
 |
ResMed
RMD
|
$ 222.3 | 0.15 % | $ 32.3 B | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
- | - | $ 28.6 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Masimo Corporation
MASI
|
- | - | $ 9.59 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |